CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 328 enrolled
Drug / intervention
pitavastatin +1 moredrug
Likely dose
pitavastatin 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01256476
NCT01256476Phase 4Completed
CompareCT.gov

A RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GROUP STUDY OF PITAVASTATIN 4 MG VS. PRAVASTATIN 40 MG IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA

Kowa Research Institute, Inc.·interventional·Posted Dec 8, 2010·Updated May 8, 2012

In Brief

A Phase 4 clinical trial evaluating pitavastatin and pravastatin for Primary Dyslipidemia and Mixed Dyslipidemia. Completed, enrolled 328 participants across 44 sites.

Detailed Summary

Randomized, double-blind, double-dummy, 12-week, active-controlled study of pitavastatin 4 mg daily(QD) vs. pravastatin 40 mg daily(QD) in subjects with primary hyperlipidemia or mixed dyslipidemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Dyslipidemia, Mixed Dyslipidemia
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 8, 2010
Enrollment StartOct 1, 2010
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.6 years ago

Interventions

pitavastatindrug

pitavastatin 4 mg once daily (QD)

pravastatindrug

Pravastatin 40 mg once daily (QD)